发明名称 IMPROVED CANCER TREATMENTS AND DIAGNOSTICS
摘要 Cancer cells that exhibit low levels of NMNAT are refractory to tiazofurin therapy, and diagnostic methods for assessing NMNAT levels, particularly human NMNAT2, are described, as are compositions and methods for enhancing cytotoxicity towards tiazofurin (2-beta-D-ribofuranosylthiazole4-carboxamide), a pro-drug metabolized by nicotinamide mononucleotide adenylyltransferase (NMNAT) to TAD (thiazole-4-carboxamide adenine dinucleotide). Examples of such compositions include gene delivery vehicles that provide for enhanced NMNAT expression in transfected cells, as well as targeted drug delivery compositions that include tiazofurin encapsulated in folate-tethered nanoparticles. This approach shows that increasing NMNAT levels, particularly hNMNAT2 levels, enhances tiazofurin-mediated cell killing, which has relevance in the treatment of various disease, including various cancers and infectious diseases.
申请公布号 WO2013130672(A2) 申请公布日期 2013.09.06
申请号 WO2013US28101 申请日期 2013.02.27
申请人 UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 发明人 JAYARAM, HIREMAGALUR, N.
分类号 A61K31/00 主分类号 A61K31/00
代理机构 代理人
主权项
地址